Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.

Yee Soo KimSimerjeet BrarNatalie D'AlboAmit DeySachin ShahSarju GanatraSourbha S Dani

Published in: Cardiovascular drugs and therapy (2021)

With increased uptake of sacubitril/valsartan, risks of hypotension, renal dysfunction, hyperkalemia, and angioedema appear low and acceptable in RCTs and global clinical practice.

Keyphrases

clinical practice
ejection fraction
adverse drug
oxidative stress
angiotensin converting enzyme
human health
drug induced
emergency department
risk assessment
clinical trial
angiotensin ii
electronic health record